秋水仙碱治疗心肌心包炎的疗效与安全性
倾向性评分匹配后,秋水仙碱组复发率显著低于对照组(19.2% vs 43.8%,p=0.001),无事件生存期更长(p=0.005),不良反应轻微。
要点
- 秋水仙碱可降低首次心包炎合并心肌炎患者的复发率。
- 女性及使用糖皮质激素是复发的独立危险因素。
- 秋水仙碱相关不良反应轻微,发生率低。
核心结论
- 在首次心包炎合并心肌受累患者中,秋水仙碱安全有效,可减少复发。
研究设计与样本
- 双中心回顾性队列研究,纳入连续收治的首次心包炎合并心肌炎患者175例,平均年龄46.2±20.1岁,女性25.1%,88.6%为特发性/病毒病因。
主要发现
- 中位随访25.3(IQR 8.3-45.6)个月,58例(33.1%)出现复发。
- 倾向性评分匹配后两组各73例,秋水仙碱组复发率19.2% vs 43.8%(p=0.001),无事件生存期更长(p=0.005)。
- 多变量分析显示女性(HR 1.97,95%CI 1.04-3.73;p=0.037)和糖皮质激素使用(HR 2.27,95%CI 1.15-4.47;p=0.018)是复发的独立危险因素。
- 秋水仙碱相关不良反应轻微,发生于3例(1.7%)患者。
临床怎么用
- 对于首次急性心包炎合并心肌炎患者,可考虑使用秋水仙碱以降低复发风险。
- 对女性和使用糖皮质激素的患者应加强复发监测。
局限性
- 回顾性队列设计可能存在选择偏倚和未测量混杂。
- 样本量有限,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical trials have evaluated the efficacy and safety of colchicine only in simple pericarditis, excluding cases of concomitant myocarditis. The aim of this paper is to evaluate the efficacy and safety of colchicine for the treatment of the first attack of acute pericarditis with concomitant myocardial involvement. METHODS: Double-centre retrospective cohort study analysing consecutive patients admitted for first attack of pericarditis with myocarditis and treated with or without colchicine. The primary efficacy end point was the time to the first recurrence. Propensity score matching was used to generate two groups of patients with similar baseline characteristics. Colchicine-associated side effects were analysed as safety end-point. RESULTS: A total of 175 patients (mean age 46.2±20.1 years, 25.1% females, 88.6% with idiopathic/viral aetiology) were included. Seventy-nine (45.1%) patients were treated with colchicine. After a median follow-up of 25.3 (IQR 8.3-45.6) months, 58 (33.1%) patients had recurrences. The propensity score generated two groups of 73 patients with similar baseline characteristics but the use of colchicine. Patients treated with colchicine had a lower incidence of recurrences (respectively, 19.2% vs 43.8%; p=0.001) and a longer event-free survival (p=0.005). In multivariable analysis, women (HR 1.97, 95% CI 1.04 to 3.73; p=0.037) and corticosteroid use (HR 2.27, 95% CI 1.15 to 4.47; p=0.018) were independent risk factors for recurrences. Colchicine-associated side effects were mild and occurred in 3 (1.7%) patients. CONCLUSION: In patients with first attack of pericarditis associated with myocardial involvement, colchicine was safe and efficacious for the reduction of recurrences.
引用
- Collini V, De Martino M, Andreis A, et al. Efficacy and safety of colchicine for the treatment of myopericarditis. Heart. 2024. PMID: 38238076. doi:10.1136/heartjnl-2023-323484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。